Trials / Completed
CompletedNCT00056381
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).
Detailed description
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anidulafungin |
Timeline
- Start date
- 2003-07-01
- Completion
- 2004-06-01
- First posted
- 2003-03-12
- Last updated
- 2008-10-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00056381. Inclusion in this directory is not an endorsement.